ERJ Open Research,
Год журнала:
2024,
Номер
unknown, С. 00438 - 2024
Опубликована: Авг. 22, 2024
In
patients
with
COPD,
dual
bronchodilator
(long-acting
muscarinic
antagonist
(LAMA)/long-acting
β2-agonist
(LABA))
and
triple
therapy
(inhaled
corticosteroid/LAMA/LABA)
reduce
the
risk
of
exacerbations
lung
function
decline
in
short-mid-term,
but
their
long-term
impact
is
unknown.
This
modelling
study
explores
these
therapies
on
decline,
quality
life
(QoL)
all-cause
mortality.
approach
used
a
longitudinal
nonparametric
superposition
model
using
published
data
regarding
exacerbations,
QoL
(assessed
by
St
George's
Respiratory
Questionnaire
(SGRQ))
The
simulated
disease
progression
from
40
to
75
years
age
assessed
initiating
at
45
("LAMA/LABA
only"
group)
escalation
50
("Escalation
triple"
forced
expiratory
volume
1
s
(FEV1)
Model
simulation
predicted
that
age,
"LAMA/LABA
preserves
159.1
mL
FEV1
versus
no
treatment,
while
"Escalation
an
additional
376.5
217.3
pharmacotherapy
only",
respectively.
SGRQ
score
reduces
(-3.2)
which
further
-7.5
triple".
mortality
5.4%
shows
decrease
12.0%.
Early
initiation
could
slow
preserving
improving
survival
COPD.
Research Square (Research Square),
Год журнала:
2024,
Номер
unknown
Опубликована: Март 28, 2024
Abstract
Background
Despite
studies
on
trace
metals
and
Chronic
Respiratory
Diseases
(CRDs),
their
causal
relationship
in
American
adults
is
uncertain.
Our
research
applied
observational
bidirectional
Mendelian
randomization
(MR)
methods
to
ascertain
this
association.
Objective
The
aim
of
study
was
evaluate
the
potential
linkages
between
serum
levels
copper
(Cu),
zinc
(Zn),
selenium
(Se)
incidence
chronic
respiratory
diseases
within
adult
demographic
United
States.
Methods
Drawing
National
Health
Nutrition
Examination
Survey
(NHANES)
2013–2016
data,
our
incorporated
2807
examine
Cu,
Zn,
Se
impacts
CRDs
risks
using
logistic
regression
cubic
spline
analysis.
Subsequently,
MR
assessments
were
conducted
causative
pertaining
these
associations.
Results
Employing
adjusted-weighted
models,
high
Cu
significantly
escalated
for
emphysema
(OR:
3.83)
obstructive
pulmonary
disease
(COPD)
2.14–3.33),
while
elevated
Zn
corresponded
respective
OR
1.82
1.91
tracheitis
COPD.
Conversely,
moderate
reduced
risk
0.64).
indicated
no
genetic
causation
(
p
>
0.05),
yet
exposure
causally
linked
COPD
=
0.003),
as
0.014).
selenium’s
protective
association
with
confirmed
0.010).
Conclusion
High
links
increased
emphysema,
tracheitis,
risk;
equally
raises
may
lessen
risk.
This
observation
warrants
confirmation
through
additional
large-scale,
prospective
cohort
sufficient
sample
sizes
extended
follow-up
durations.
Frontiers in Medicine,
Год журнала:
2024,
Номер
11
Опубликована: Май 13, 2024
Chronic
obstructive
pulmonary
disease
(COPD)
is
a
major
cause
of
illness
and
death
among
adults.
In
2019,
the
Global
Initiative
for
Obstructive
Lung
Disease
(GOLD)
strategy
incorporated
blood
eosinophils
as
biomarker
to
identify
patients
at
increased
risk
exacerbations
which,
with
history
during
previous
year,
allows
identification
who
would
benefit
from
anti-inflammatory
treatment
reduce
future
exacerbations.
The
aim
this
study
was
describe
demographic
clinical
characteristics,
eosinophil
counts,
in
cohort
COPD
stratified
by
phenotypes
(non-exacerbator,
frequent
exacerbator,
asthma-COPD
overlap)
Colombian
2600
meters
above
sea
level.
Temperature
fluctuations
can
impact
the
occurrence
and
progression
of
respiratory
system
diseases.
However,
current
understanding
temperature
on
acute
exacerbation
chronic
obstructive
pulmonary
disease
(AECOPD)
remains
limited.
Therefore,
our
study
aims
to
investigate
relationship
between
daily
mean
(DMT)
risk
AECOPD
hospitalizations
within
Panzhihua
City.
ERJ Open Research,
Год журнала:
2024,
Номер
unknown, С. 00438 - 2024
Опубликована: Авг. 22, 2024
In
patients
with
COPD,
dual
bronchodilator
(long-acting
muscarinic
antagonist
(LAMA)/long-acting
β2-agonist
(LABA))
and
triple
therapy
(inhaled
corticosteroid/LAMA/LABA)
reduce
the
risk
of
exacerbations
lung
function
decline
in
short-mid-term,
but
their
long-term
impact
is
unknown.
This
modelling
study
explores
these
therapies
on
decline,
quality
life
(QoL)
all-cause
mortality.
approach
used
a
longitudinal
nonparametric
superposition
model
using
published
data
regarding
exacerbations,
QoL
(assessed
by
St
George's
Respiratory
Questionnaire
(SGRQ))
The
simulated
disease
progression
from
40
to
75
years
age
assessed
initiating
at
45
("LAMA/LABA
only"
group)
escalation
50
("Escalation
triple"
forced
expiratory
volume
1
s
(FEV1)
Model
simulation
predicted
that
age,
"LAMA/LABA
preserves
159.1
mL
FEV1
versus
no
treatment,
while
"Escalation
an
additional
376.5
217.3
pharmacotherapy
only",
respectively.
SGRQ
score
reduces
(-3.2)
which
further
-7.5
triple".
mortality
5.4%
shows
decrease
12.0%.
Early
initiation
could
slow
preserving
improving
survival
COPD.
